Skip to main content

Table 3 Association of functional outcomes grouped by different levels of Lp(a) and Lp-PLA2

From: Elevated lipoprotein(a) and lipoprotein-associated phospholipase A2 are associated with unfavorable functional outcomes in patients with ischemic stroke

 

Event rate

OR (95% confidence interval)

Unadjusted

Adjusted

mRS ≥ 3 at 3 months

 Lp(a) < median and Lp-PLA2 < median

12.80

Reference

Reference

 Lp(a) < median and Lp-PLA2 ≥ median

12.92

1.01 (0.85–1.17)

0.96 (0.79–1.17)

 Lp(a) ≥ median and Lp-PLA2 < median

14.64

1.17 (0.99–1.38)

1.08 (0.90–1.30)

 Lp(a) ≥ median and Lp-PLA2 ≥ median

17.28

1.42 (1.22–1.66)

1.21 (1.01–1.46)

mRS ≥ 3 at 1 year

 Lp(a) < median and Lp-PLA2 < median

12.11

Reference

Reference

 Lp(a) < median and Lp-PLA2 ≥ median

12.82

1.07 (0.90–1.27)

1.08 (0.89–1.32)

 Lp(a) ≥ median and Lp-PLA2 < median

14.26

1.21 (1.02–1.43)

1.14 (0.95–1.37)

 Lp(a) ≥ median and Lp-PLA2 ≥ median

15.61

1.34 (1.14–1.58)

1.25 (1.03–1.51)

  1. Adjust for age, sex, BMI, Diabetes mellitus, LDL-C, HDL-C, TG, TOAST subtypeand NIHSS score at admission
  2. BMI: body mass index; LDL-C: low-density lipoprotein cholesterol; HDL-C: high-density lipoprotein cholesterol; TG: triglyceride; NIHSS: National Institutes of Health Stroke Scale